Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK.
Qkine Ltd
We manufacture high quality growth factors and cytokines for stem cell, organoid and regenerative medicine applications.
Spun-out from the University of Cambridge in 2016, we use proprietary protein purification and engineering technology to make recombinant proteins in E.coli. Our proteins are properly folded, free from contaminating related TGF beta family proteins (unfortunately often present in mammalian protein expression systems) and we include full QC data for every batch – mass spec, analytical reverse phase, recovery, SDS-PAGE, bioassay data and endotoxin testing.
Telephone: +44 (0)1223 491 486
Address :
152 Cambridge Science Park Milton Road Cambridge
Post Code: CB4 0GN
Country: United Kingdom
Website: http://www.qkine.com
Membership Type: Professional Individual and Corporate <5
Qkine is a Cambridge-based manufacturer of high purity growth factors and cytokines for use in stem cell science and regenerative medicine applications. Spun-out from Dr Marko Hyvönen’s laboratory at the University of Cambridge in 2016, Qkine builds on expertise in protein purification and structural biology developed at the University and existing collaborations with the stem cell community to address the need for high quality growth factors. Qkine’s new product development programme uses protein engineering and other innovative hypothesis-led techniques to address challenges in protein production for stem cell and organoid biology. For more information, please visit: www.qkine.com
There are no Products & Services to display
26-11-2020
Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board strengthening the company’s leadership team in preparation for scaling commercial operations internationally.
22-07-2020
Qkine today announced the successful closure of a £1.5M Series A investment round to accelerate the global scale-up of its commercial operations and make key hires to its leadership team.
08-06-2020
Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications has closed a further round of investment. The £550k funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018.
03-06-2019
University of Cambridge spin-out Qkine has closed its seed investment round supported by Cambridge Enterprise, the commercialisation arm of the University, and a team of five angels led by Jim Warwick. The amount is undisclosed.
23-04-2018
There are no events to display
There are no jobs to display
No Blog articles found
